CATHY DAVIS: Open Payments
NPI 1891152906 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$912 in 33 payments from 9 companies in 2025. Trend: 2023 $1,803 · 2024 $1,399 · 2025 $912
Food & beverage: $912
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $243 |
| Otsuka America Pharmaceutical, Inc. | 5 | $241 |
| Teva Pharmaceuticals USA, Inc. | 6 | $189 |
| Alkermes, Inc. | 4 | $78 |
| Lundbeck LLC | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: INGREZZA, ABILIFY MAINTENA, AUSTEDO XR, ABILIFY ASIMTUFII, VIVITROL, CAPLYTA, INVEGA SUSTENNA, UZEDY.
Industry payments across LA — which companies pay providers there.
